酿酒酵母菌血症：危险因素、结局及与含布拉氏酵母菌的益生菌制剂应用的关系。

Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration.

机构信息

Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium.

出版信息

Infect Dis Now. 2021 May;51(3):293-295. doi: 10.1016/j.idnow.2020.12.003. Epub 2020 Dec 31.

DOI:10.1016/j.idnow.2020.12.003

PMID:33934809

Abstract

UNLABELLED

Saccharomyces cerevisiae fungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration.

OBJECTIVE

The aim of our study was to review cases of S. cerevisiae fungemia along with the corresponding risk factors (including S. boulardii probiotic intake), treatment and outcomes.

PATIENTS AND METHODS

Retrospective study (2005-2017) of S. cerevisiae fungemia. All the data were extracted from medical files.

RESULTS

We identified 10 patients with S. cerevisiae fungemia. Mean age was 59.4 years (range 21-88). Four fifths (80%) were on total parenteral or enteral nutrition, 70% had a central venous line, and 30% were admitted in an Intensive Care Unit (ICU). S. boulardii-containing probiotic prescription was identified in 6 subjects. Three patients with no risk factors such as ICU or central venous catheter were 80 years old or more. Mortality rate was 50%.

CONCLUSION

S. cerevisiae fungemia is a rare but life-threatening infection, associated with intake of probiotics containing S. boulardii. Besides classical risk factors, older age should be a contraindication for these probiotics.

摘要

目的

本研究旨在回顾酵母菌性菌血症的病例，并探讨其相关危险因素（包括摄入含有布拉氏酵母菌的益生菌）、治疗和预后。

方法

这是一项回顾性研究（2005-2017 年），分析了酵母菌性菌血症患者的病例资料。所有数据均从病历中提取。

结果

共发现 10 例酵母菌性菌血症患者，平均年龄 59.4 岁（21-88 岁）。80%的患者接受全肠外或肠内营养，70%的患者有中心静脉导管，30%的患者入住重症监护病房（ICU）。6 例患者处方了含有布拉氏酵母菌的益生菌。3 例无 ICU 或中心静脉导管等危险因素的患者年龄均在 80 岁以上。死亡率为 50%。